Acumen Pharmaceuticals Inc’s recently made public that its CFO & Chief Business Officer Zuga Matt unloaded Company’s shares for reported $49633.0 on Jan 23 ’25. In the deal valued at $1.72 per share,28,902 shares were sold. As a result of this transaction, Zuga Matt now holds 231,744 shares worth roughly $0.27 million.
Then, Zuga Matt sold 4,364 shares, generating $6,986 in total proceeds. Upon selling the shares at $1.60, the CFO & Chief Business Officer now owns 260,646 shares.
Before that, OConnell Daniel Joseph sold 12,619 shares. Acumen Pharmaceuticals Inc shares valued at $20,102 were divested by the Chief Executive Officer at a price of $1.59 per share. As a result of the transaction, OConnell Daniel Joseph now holds 667,488 shares, worth roughly $0.79 million.
Citigroup initiated its Acumen Pharmaceuticals Inc [ABOS] rating to a Buy in a research note published on July 26, 2024; the price target was $7. A number of analysts have revised their coverage, including Deutsche Bank’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Cantor Fitzgerald started covering the stock on May 18, 2023. It rated ABOS as “an Overweight”.
Price Performance Review of ABOS
On Tuesday, Acumen Pharmaceuticals Inc [NASDAQ:ABOS] saw its stock fall -7.09% to $1.18. Over the last five days, the stock has gained 13.46%. Acumen Pharmaceuticals Inc shares have fallen nearly -31.40% since the year began. Nevertheless, the stocks have fallen -52.61% over the past one year.
How much short interest is there in Acumen Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acumen Pharmaceuticals Inc stocks on 2025-05-15, growing by 0.12 million shares to a total of 1.88 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 1.76 million shares. There was a rise of 6.29%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 15, 2022 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $15 price target.
